Shimadzu, Indigo BioSystems Partner on Clinical Mass Spec Workflows | GenomeWeb

NEW YORK (GenomeWeb News) – Shimadzu and Indigo BioSystems announced that they have formed a partnership for the development of clinical mass spectrometry workflows.

Under the partnership, the two firms will combine Shimadzu's mass spec instruments with Indigo's Ascent clinical analysis software, a platform for interpreting mass spec data and automatically reviewing that data for problematic results.

The partnership will focus on developing mass spec solutions for applications in clinical research, forensic toxicology, and drug development, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.